For the quarter ending 2025-12-31, CTOR made $3,944,111 in revenue. -$5,534,069 in net income. Net profit margin of -140.31%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 3,944,111 | - | 0 | - |
| Cost of revenues | 789,208 | - | - | - |
| Gross profit | 3,154,903 | - | - | - |
| Research and development | 1,018,352 | 1,076,136 | 938,277 | 3,139,413 |
| Amortization of in-process research and development | 573,438 | - | - | - |
| General and administrative | 2,859,339 | 1,337,244 | 1,881,447 | 2,243,327 |
| Revenues | - | - | 0 | - |
| Stock-based compensation general and administrative | 3,956,050 | 2,298,132 | 2,125,237 | 2,088,572 |
| Total operating expenses | 8,407,179 | 4,711,512 | 4,944,961 | 7,471,312 |
| Operating loss | -5,252,276 | -4,687,001.25* | -4,944,961 | - |
| Interest income | 28,288 | 9,093.25* | - | - |
| Interest expense | 45,841 | 54,508* | 160,755 | - |
| Total other income (expense), net | -17,553 | -45,414.75* | - | - |
| Loss before income taxes | -5,269,829 | -4,732,416 | -5,105,716 | -7,471,312 |
| Income tax expense | 264,240 | 264,240 | 264,240 | 264,240 |
| Net loss | -5,534,069 | -4,996,656 | -5,369,956 | -7,735,552 |
| Basic EPS | -0.06 | -0.064 | -0.08 | -0.11 |
| Diluted EPS | -0.06 | -0.064 | -0.08 | -0.11 |
| Basic Average Shares | 87,462,385 | 78,414,670 | 71,552,402 | 71,552,402 |
| Diluted Average Shares | 87,462,385 | 78,414,670 | 71,552,402 | 71,552,402 |
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)